



1646

Patent
Attorney's Docket No. 002010-680

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	BOX NON-FEE AMENDMENT
)	
Konradi et al.)	Group Art Unit: 1646
)	
Application No.: 09/910,702)	Examiner: T.N. Truong
)	
Filed: July 20, 2001)	Confirmation No.: 2073
)	
For: ALPHA AMINO ACID DERIVATIVES-)	
INHIBITORS OF LEUKOCYTE)	
ADHESION MEDIATED BY VLA-4)	
)	

RECEIVED
NOV 22 2002
TECH CENTER 1600/2900

AMENDMENT/REPLY TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is a reply for the above-identified patent application.

- ☒ A Petition for Extension of Time is also enclosed.
- ☐ A Terminal Disclaimer and a check for ☐ \$55.00 (2814) ☐ \$110.00 (1814) to cover the requisite Government fee are also enclosed.
- ☐ Also enclosed is _____
- ☐ Small entity status is hereby claimed.
- ☐ Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the ☐ \$370.00 (2801) ☐ \$740.00 (1801) fee due under 37 C.F.R. § 1.17(e).
- ☐ Applicant(s) previously submitted ___, on ___, for which continued examination is requested.
- ☐ Applicant(s) request suspension of action by the Office until at least __, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.
- ☐ A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.
- ☒ No additional claim fee is required.

☐ An additional claim fee is required, and is calculated as shown below:

AMENDED CLAIMS					
	NO. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADDT'L FEE
Total Claims		MINUS =		× \$18.00 (1202) =	
Independent Claims		MINUS =		× \$84.00 (1201) =	
If Amendment adds multiple dependent claims, add \$280.00 (1203)					
Total Amendment Fee					
If small entity status is claimed, subtract 50% of Total Amendment Fee					
TOTAL ADDITIONAL FEE DUE FOR THIS AMENDMENT					


☐ A claim fee in the amount of \$_____ is enclosed.

☐ Charge \$_____ to Deposit Account No. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Gerald F. Swiss
Registration No. 30,113

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

Date: November 15, 2002



#8
11/29/02
Patent *Stefes*

Attorney's Docket No. 002010-680

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Konradi, et al.)	Confirmation No. 2073
Application No.: 09/910,702)	Group Art Unit: 1646
Filed: July 20, 2001)	Examiner: T. N. Truong
For: Alpha Amino Acid Derivatives-)	
Inhibitors of Leukocyte Adhesion)	
Mediated by VLA-4)	

REPLY PURSUANT TO 37 C.F.R. §1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Reply is in response to the Office Action mailed September 23, 2002. This Office Action, in the form of an election of species requirement, set a one-month period for response. A Petition requesting a one-month extension of time accompanies this response which is being filed on or before its now current due date of November 23, 2002.

In response to this Office Action, consideration of the following remarks is earnestly solicited.

REMARKS


It is respectfully requested that the claims in this application be examined in view of the following remarks.

RECEIVED
NOV 22 2002
TECH CENTER 1600/2900


Election of Species Requirement

In this Office Action, it is alleged that the claims of this application are generic to a plurality of patentably distinct species disclosed in the application, corresponding to compounds of formulae Ia, Ib, IIa, IIb, IIc, IId, and IIe.

In response to this requirement, Applicants elect, without traverse, the compounds of Group IIc which are represented by the formula:



In addition, if an ultimate species is required, Applicants elect, without traverse, the compound of example 1, i.e., *N*-(5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-2-pyridon-3-yl)phenylalanine which is represented by the formula:




Applicants believe that Claims 1, 3, 6-12, 14 and 17-21 read on the elected species.

Early examination of this application is requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Gerald F. Swiss
Registration No. 30,113

P.O. Box 1404
Arlington, VA 22313-1404
Firm Phone: (650) 622-2300

Date: November 15, 2002